Markets:

Overview

News

Currencies

International

Treasuries

Aura Biosciences, Inc. - Common Stock (NQ:AURA)

5.660 +0.060 (+1.07%)

Streaming Delayed Price Updated: 2:40 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aura Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >

12 Health Care Stocks Moving In Monday's Intraday Session ↗

October 03, 2022

Gainers

Via Benzinga

Why Tesla Shares Are Trading Lower By Over 7%, Here Are 52 Stocks Moving In Monday's Mid-Day Session ↗

October 03, 2022

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) gained 641% to $2.0207 after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion, for $2.07 per share.

Via Benzinga

JMP Is Bullish On This Cancer Stock "Sees New Way to Treat Cancer" ↗

July 19, 2022

Via Benzinga

Aura Biosciences' Belzupacap Sarotalocan At Par With Plaque Radiotherapy In Eye Cancer ↗

June 23, 2022

Via Benzinga

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022

October 03, 2022

From Aura Biosciences, Inc.

Via Business Wire

Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday ↗

September 29, 2022

Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial...

Via Benzinga

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

September 28, 2022

From Aura Biosciences, Inc.

Via Business Wire

Aura Biosciences to Present Ongoing Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2022

September 27, 2022

From Aura Biosciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 14, 2022

Via Benzinga

Aura Biosciences to Present Phase 2 Safety Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) in Patients with Choroidal Melanoma at the ESMO 2022 Congress

September 07, 2022

From Aura Biosciences Inc.

Via Business Wire

Aura Biosciences to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

September 01, 2022

From Aura Biosciences Inc.

Via Business Wire

Bed Bath & Beyond, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday ↗

August 18, 2022

Bed Bath & Beyond Inc. (NASDAQ: BBBY) fell 23.3% to $17.71 following a Form 144 filing by RC Ventures, which suggested the firm proposed to sell 7.78 million common shares and certain call options....

Via Benzinga

This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday ↗

August 19, 2022

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

August 17, 2022

Via Benzinga

Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session ↗

August 18, 2022

Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66.

Via Benzinga

Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

August 11, 2022

From Aura Biosciences Inc.

Via Business Wire

Aura Biosciences to Participate at the 2022 BTIG Biotechnology Conference

August 02, 2022

From Aura Biosciences, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022 ↗

July 19, 2022

Upgrades

Via Benzinga

Aura Biosciences' Stock Gains As FDA Grants Fast Track Status To Bladder Cancer Drug ↗

June 30, 2022

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Aura Biosciences’ (NASDAQ: AURA) belzupacap sarotalocan (AU-011) for the treatment of Non-Muscle Invasive Bladder...

Via Benzinga

The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial ↗

June 30, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Aura Biosciences Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

June 30, 2022

From Aura Biosciences, Inc.

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

June 22, 2022

Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.3% to $1.03 during Wednesday's after-market session. The company's market cap stands at $33.2 million.

Via Benzinga

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

June 22, 2022

From Aura Biosciences Inc.

Via Business Wire

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗

June 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Aura Biosciences to Present Updated Belzupacap Sarotalocan (AU-011) Data on Multiple Studies at the International Society of Ocular Oncology 2022 Bi-Annual Meeting

June 17, 2022

From Aura Biosciences Inc.

Via Business Wire

Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

May 26, 2022

From Aura Biosciences Inc.

Via Business Wire

Aura Biosciences to Participate in Upcoming Investor Conferences

May 25, 2022

From Aura Biosciences Inc.

Via Business Wire

Aura Biosciences Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

May 12, 2022

From Aura Biosciences Inc.

Via Business Wire

Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

May 03, 2022

From Aura Biosciences Inc.

Via Business Wire

Aura Biosciences to Present at the 2022 Bank of America Healthcare Conference

May 03, 2022

From Aura Biosciences Inc.

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Aura Biosciences, Inc. - Common Stock (NQ:AURA)

All News about Aura Biosciences, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today